MARCH-APRIL 2025 Shooting Cancer Highlights: Periodic focus on regulatory status of new targeted therapies in oncology
EMA March 11 – Amivantamab – NSCLC EGFR. The European Commission (EC) has approved a Type II variation extension of indication for the anti-EGFR-MET bispecific antibody to include the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions (ex19del) or exon 21 L858R substitution mutations, in combination with […]